Change in objective cough count correlates with improvement in patient-reported outcomes of cough in patients with idiopathic pulmonary fibrosis

This study examined the correlation between change in 24-hour cough count and patient-reported outcomes in adult patients with idiopathic pulmonary fibrosis and self-reported chronic cough treated with nalbuphine extended-release tablets or placebo in a randomized, double-blind, placebo-controlled, Phase 2a crossover trial. During the trial, 24-hour cough count was measured at baseline and treatment end using the Vitalograph VitaloJAK digital cough monitor.